[Editor’s Note: See the July 2016 Report #S290, “Worldwide Market for Sealants, Glues, and Hemostats, 2015-2022”.]
Products to accelerate the process of stopping the bleeding (hemostasis) from surgical or traumatic wounds are numerous and there are many manufacturers as a result of low barriers to market entry.
Primarily these products were first introduced to prevent hematomas during surgery with the aim of preventing resultant infections. During the 1980s and 1990s, the popularity of hemostats increased rapidly as surgeons tried to avoid excessive use of blood transfusions for reasons of economy and the threat of disease transmission. Products were launched during this period by many of the large medical device manufacturers, such as Johnson & Johnson, which now sells Surgicel (an oxidized regenerated cellulose hemostat), Instat (a freeze-dried collagen product), and Spongostan/Surgifoam (a freeze-dried gelatin hemostat).
Hemostats fall into a number of categories based on their active ingredients:
Source: MedMarket Diligence, LLC; Report #S180. (See the July 2016 Report #S290, “Worldwide Market for Sealants, Glues, and Hemostats, 2015-2022”.)